All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On 20th December 2016, JCAR017 (an active CAR T-cell therapy specific to CD19) was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment for patients with DLBCL, PMBCL, grade 3B FL, or Not Otherwise Specified Disease (NOS; de novo or transformed from indolent lymphoma).
Furthermore, on the 15th December 2016, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) have allowed JCAR017 access to the Priority Medicines (PRIME) scheme (a similar status to the FDA Breakthrough Designation Therapy status) for R/R DLBCL.
The phase I TRANSCEND (NCT02631044) study, which evaluated the safety and pharmacokinetics of Juno Therapeutics’ and Celgene’s investigational drug in R/R NHL patients, was presented at the American Society of Hematology’s 2016 Annual Meeting (abstract 4192) by Jeremy S. Abramson, MD, from the Massachusetts General Hospital, Boston, MA.
The authors of the abstract concluded by stating that treatment with JCAR017 resulted in high CR rates in heavily pretreated patients with DLBCL. It was also reported that toxicities were manageable and there were fewer AEs reported with JCAR017 compared to other CD19 specific CAR T-cell therapies.
This Breakthrough Therapy Designation emphasizes the need for novel therapies to treat patients with DLBCL, especially for those who are unresponsive to initial treatment or who have relapsed.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox